Severe liver dysfunction after raltitrexed administration in an HCV-positive colorectal cancer patient

Cancer Invest. 2003;21(1):162-3. doi: 10.1081/cnv-120016411.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / complications
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Adenocarcinoma / surgery
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antiviral Agents / therapeutic use
  • Chemical and Drug Induced Liver Injury / etiology*
  • Colectomy / methods
  • Colonic Neoplasms / complications
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / surgery
  • Combined Modality Therapy
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects*
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Interferon-alpha / therapeutic use
  • Liver Function Tests
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Male
  • Middle Aged
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Quinazolines / administration & dosage
  • Quinazolines / adverse effects*
  • Thiophenes / administration & dosage
  • Thiophenes / adverse effects*
  • Viremia / complications

Substances

  • Antiviral Agents
  • Enzyme Inhibitors
  • Interferon-alpha
  • Organoplatinum Compounds
  • Quinazolines
  • Thiophenes
  • Oxaliplatin
  • raltitrexed